PureTech Health plc (PTCHF)
USD 1.75
(-5.91%)
USD 1.75
(-5.91%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -146.19 Million USD | 26.09% |
| 2022 | -197.8 Million USD | -31.62% |
| 2021 | -150.28 Million USD | -25.73% |
| 2020 | -119.53 Million USD | 11.72% |
| 2019 | -135.39 Million USD | -30.17% |
| 2018 | -104.01 Million USD | 9.88% |
| 2017 | -115.42 Million USD | -56.12% |
| 2016 | -73.92 Million USD | -69.4% |
| 2015 | -43.64 Million USD | -150.17% |
| 2014 | -17.44 Million USD | -367.57% |
| 2013 | -3.73 Million USD | 60.25% |
| 2012 | -9.38 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -33.19 Million USD | 0.0% |
| 2024 Q1 | -33.19 Million USD | 52.22% |
| 2023 Q2 | -76.16 Million USD | -100.0% |
| 2023 Q1 | -38.08 Million USD | 62.42% |
| 2023 FY | -146.2 Million USD | 26.09% |
| 2023 Q4 | -69.48 Million USD | -98.41% |
| 2023 Q3 | -35.01 Million USD | 54.02% |
| 2022 Q4 | -101.34 Million USD | -109.79% |
| 2022 Q2 | -101.19 Million USD | -100.0% |
| 2022 Q3 | -48.3 Million USD | 52.26% |
| 2022 FY | -197.8 Million USD | -31.62% |
| 2022 Q1 | -50.59 Million USD | 39.02% |
| 2021 FY | -150.28 Million USD | -25.73% |
| 2021 Q2 | -68.08 Million USD | -100.0% |
| 2021 Q4 | -82.96 Million USD | -101.86% |
| 2021 Q3 | -41.1 Million USD | 39.63% |
| 2021 Q1 | -34.04 Million USD | 48.07% |
| 2020 FY | -119.53 Million USD | 11.72% |
| 2020 Q2 | -26.39 Million USD | 0.0% |
| 2020 Q3 | -33.37 Million USD | -26.46% |
| 2020 Q4 | -65.55 Million USD | -96.42% |
| 2020 Q1 | -26.39 Million USD | 59.99% |
| 2019 FY | -135.39 Million USD | -30.17% |
| 2019 Q3 | -32.54 Million USD | 53.72% |
| 2019 Q4 | -65.95 Million USD | -102.69% |
| 2019 Q2 | -70.31 Million USD | -100.0% |
| 2019 Q1 | -35.15 Million USD | -36.06% |
| 2018 Q4 | -25.83 Million USD | 0.0% |
| 2018 FY | -104.01 Million USD | 9.88% |
| 2018 Q2 | -26.17 Million USD | 0.0% |
| 2018 Q1 | -26.17 Million USD | 10.09% |
| 2018 Q3 | -25.83 Million USD | 1.26% |
| 2017 Q3 | -29.1 Million USD | -2.92% |
| 2017 Q1 | -28.28 Million USD | -43.69% |
| 2017 Q2 | -28.28 Million USD | 0.0% |
| 2017 FY | -115.42 Million USD | -56.12% |
| 2017 Q4 | -29.1 Million USD | 0.0% |
| 2016 Q2 | -17.28 Million USD | 0.0% |
| 2016 FY | -73.92 Million USD | -69.4% |
| 2016 Q1 | -17.28 Million USD | -7.88% |
| 2016 Q4 | -19.68 Million USD | 0.0% |
| 2016 Q3 | -19.68 Million USD | -13.9% |
| 2015 Q3 | -16.01 Million USD | -176.03% |
| 2015 Q1 | -5.8 Million USD | 7.35% |
| 2015 FY | -43.64 Million USD | -150.17% |
| 2015 Q4 | -16.01 Million USD | 0.0% |
| 2015 Q2 | -5.8 Million USD | 0.0% |
| 2014 Q2 | -2.45 Million USD | 0.0% |
| 2014 Q4 | -6.26 Million USD | 0.0% |
| 2014 Q1 | -2.45 Million USD | 0.0% |
| 2014 FY | -17.44 Million USD | -367.57% |
| 2014 Q3 | -6.26 Million USD | -154.72% |
| 2013 FY | -3.73 Million USD | 60.25% |
| 2012 FY | -9.38 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -10847.702% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -2798.196% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -719.18% |
| Nascent Biotech, Inc. | -2.22 Million USD | -6456.365% |
| Rebus Holdings, Inc. | -664 Thousand USD | -21917.922% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 278.614% |
| Qrons Inc. | -643.67 Thousand USD | -22613.1% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -37428.3% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | -163.384% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -35088.06% |
| Skye Bioscience, Inc. | -13.67 Million USD | -969.347% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | -103.659% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 3074.662% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -55759.563% |
| SQZ Biotechnologies Company | -75.82 Million USD | -92.811% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -5028.877% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -9417.86% |
| Mesoblast Limited | -84.14 Million USD | -73.742% |
| Marizyme, Inc. | -34.08 Million USD | -328.906% |
| Genus plc | 6.4 Million USD | 2384.359% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 1600.638% |
| Pharming Group N.V. | -4.87 Million USD | -2896.161% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -7259.705% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -15597.03% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -1650.886% |
| ContraFect Corporation | -56.88 Million USD | -156.99% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -3109.831% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -10327.956% |
| IMV Inc. | -38.67 Million USD | -278.053% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -5214.706% |
| MultiCell Technologies, Inc. | -722.81 USD | -20226377.221% |
| ONE Bio Corp. | 13.68 Million USD | 1168.585% |
| Accustem Sciences Inc. | -3.74 Million USD | -3802.366% |
| RVL Pharmaceuticals plc | -58.99 Million USD | -147.837% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -30165.059% |
| Q BioMed Inc. | -3.44 Million USD | -4143.044% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 4229.915% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -5464.14% |
| Biomind Labs Inc. | -1 Million USD | -14380.84% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | -165.95% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -4939.173% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -2099.138% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -7741.737% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -488010.978% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -821.244% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -7464.848% |
| GB Sciences, Inc. | -1.42 Million USD | -10192.015% |
| Alpha Cognition Inc. | -9.7 Million USD | -1406.336% |
| HST Global, Inc. | -140.9 Thousand USD | -103655.669% |
| CSL Limited | 3.7 Billion USD | 103.949% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -12896.553% |
| Halberd Corporation | -75.05 Thousand USD | -194702.132% |
| Enzolytics Inc. | -2.14 Million USD | -6703.751% |
| Agentix Corp. | -1.37 Million USD | -10557.799% |
| Resverlogix Corp. | -12.74 Million USD | -1046.749% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -4514.468% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 65.604% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -13903.736% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -4907.769% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -9156.88% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -4193.683% |
| AVAX Technologies, Inc. | 6.69 Million USD | 2284.396% |
| Zenith Capital Corp. | -8.94 Million USD | -1534.787% |
| Genscript Biotech Corporation | -415.79 Million USD | 64.838% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -839111.297% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -5854.384% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -85142.489% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -7192.605% |
| Kadimastem Ltd | -3.04 Million USD | -4708.782% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -14756.822% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -11540.048% |
| BioStem Technologies, Inc. | -7.77 Million USD | -1779.414% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -80457.071% |
| LadRx Corporation | -3.82 Million USD | -3723.57% |
| Cell Source, Inc. | -4.32 Million USD | -3280.053% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -21182.335% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -21182.335% |
| NovAccess Global Inc. | -2.46 Million USD | -5826.762% |
| Affymax, Inc. | -15.04 Million USD | -871.68% |
| Itoco Inc. | -919.14 Thousand USD | -15806.064% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -3349.38% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -12965.147% |
| Mobile Lads Corp. | -554.55 Thousand USD | -26263.538% |
| CytoDyn Inc. | -18.05 Million USD | -709.608% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -580746.246% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -66330.538% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -25788.622% |
| SYBLEU INC | -149.18 Thousand USD | -97901.743% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -7949.187% |
| International Stem Cell Corporation | -663 Thousand USD | -21951.131% |
| Bioxytran, Inc. | -3.82 Million USD | -3727.052% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -277633.663% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -718675.811% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | -303.13% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -8935.785% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -19768.449% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -4599.421% |
| Neutra Corp. | -229.48 Thousand USD | -63607.154% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -733.565% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -580.276% |
| IXICO plc | -1.43 Million USD | -10073.904% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -1440.396% |
| Gelesis Holdings, Inc. | -121.8 Million USD | -20.026% |
| CSL Limited | 3.81 Billion USD | 103.835% |
| Cellectis S.A. | -108.85 Million USD | -34.303% |